ライフサイエンスコーパス: Ga

1 Ga stress induces root secretion of organic acids such a

2 he southeastern province to be 0.85 +/- 0.08 Ga younger than the northwestern fields.

3 lt-dominated metasomatism related to the 1.1 Ga Umkondo Large Igneous Province.

4 veloped a novel technique in which with a 23 Ga fiber optic light pipe is used to identify the cut en

5 of the paleo-atmosphere at approximately 3.3 Ga.

6 However, the mid-Palaeozoic c. 0.45-0.4 Ga shows global atmospheric changes consistent with incr

7 After the Great Oxidation c. 2.4 Ga, the now oxidizing atmosphere masked that redox signa

8 e system in Gale Crater at approximately 3.5 Ga.

9 kind, this study demonstrates that over 4.5 Ga of impact processing, plagioclase is on average weakl

10 d intensification of weathering c. 0.85-0.54 Ga is currently equivocal.

11 (67)Ga-, (111)In-, and (177)Lu-NeoBOMB1 specifically and str

12 After injection in mice, all 3 ((67)Ga-, (111)In-, and (177)Lu-NeoBOMB1) showed comparably h

13 istribution was performed by injecting a (67)Ga-, (111)In-, or (177)Lu-NeoBOMB1 bolus (74, 74, or 370

14 No studies for (67)Ga citrate scintigraphy met the inclusion criteria.

15 Internalization of (67)Ga-, (111)In-, and (177)Lu-NeoBOMB1 radioligands was stu

16 (68)Ga DOTATATE SUVmax relates to grade and Ki-67 and can be

17 (68)Ga-DOTATATE approval by the U.S. Food and Drug Administr

18 (68)Ga-DOTATATE mean of maximum tissue-to-blood ratios (mTBR

19 (68)Ga-DOTATATE mTBRmax predicted high-risk coronary compute

20 (68)Ga-DOTATATE PET imaging was compared to [(18)F]FDG PET i

21 (68)Ga-DOTATATE PET/CT enables detection of meningioma tissu

22 (68)Ga-DOTATATE PET/CT in comparison to CE-MRI performed at

23 (68)Ga-DOTATATE PET/CT of the neck was performed before surg

24 (68)Ga-DOTATATE PET/CT resulted in intended management chang

25 (68)Ga-DOTATATE uptake was measured by drawing regions of in

26 (68)Ga-DOTATOC and (68)Ga-DOTATATE are radiolabeled somatost

27 (68)Ga-DOTATOC showed 26 lesions not found on (64)Cu-DOTATAT

28 (68)Ga-DOTATOC, a somatostatin receptor-targeted ligand, has

29 (68)Ga-HZ220 is a promising bimodal ligand for noninvasive P

30 (68)Ga-labeled DOTA-4-amino-1-carboxymethyl-piperidine-d-Phe

31 (68)Ga-NOTA-UBI showed moderate blood clearance (29-min half

32 (68)Ga-OPS202 ((68)Ga-NODAGA-JR11; NODAGA = 1,4,7-triazacycl

33 (68)Ga-OPS202 cleared rapidly from the blood, with a mean re

34 (68)Ga-pentixafor is a radiotracer for PET that binds with n

35 (68)Ga-pentixafor signal is higher in patients with a high-r

36 (68)Ga-prostate-specific membrane antigen (PSMA) PET/CT is a

37 (68)Ga-prostate-specific membrane antigen (PSMA)-11 PET/CT r

38 (68)Ga-PSMA (prostate-specific membrane antigen) PET/CT is i

39 (68)Ga-PSMA ligand PET/CT enables discrimination of local ve

40 (68)Ga-PSMA ligand PET/CT indicated local recurrence in 68 o

41 (68)Ga-PSMA PET/CT scanning has been shown to be more sensit

42 (68)Ga-PSMA-11 PET/CT was performed in all patients 1-2 wk b

43 (68)Ga-PSMA-11-positive lesions not covered by planning volu

44 d prostate-specific membrane antigen 11 ((68)Ga-PSMA-11) PET/CT affects the implemented management of

45 The mean time interval between the 2 (68)Ga-DOTATATE studies was 9.6 +/- 7.2 mo, and the mean tim

46 positive predictive values between the 2 (68)Ga-OPS202 peptide doses, indicating a high reproducibili

47 The 2 (68)Ga-THP-PSMA scans with negative results had only 1+/2+ s

48 el, 5 ng/mL; range, 0.25-294 ng/mL), 362 (68)Ga-PSMA PET-positive lymph nodes (LNs) were identified.

49 NeoBOMB1 was radiolabeled with (67/68)Ga, (111)In, and (177)Lu according to published protocol

50 A (68)Ga-DOTATATE TV of 35.8 mL or more was associated with in

51 A (68)Ga-DOTATATE TV of 7.0 mL or more was associated with hig

52 mented management plans before and after (68)Ga-PSMA PET/CT in 100 patients with BCR were retrospecti

53 Management changed after (68)Ga-PSMA PET/CT in 39 patients (39%).

54 -body images for both (68)Ga-DOTATOC and (68)Ga DOTATATE.

55 luorodihydroxyphenylalanine (FDOPA), and (68)Ga somatostatin-receptor ligands in NETs has been expand

56 fter injection, (68)Ga-NOTA-HACA-PD1 and (68)Ga-DOTA-HACA-PD1 exhibited promising target-to-backgroun

57 -ethyl-tyrosine ((18)F-FET) (n = 31) and (68)Ga-DOTANOC (n = 7) and studies of healthy subjects using

58 tasis for both (18)F-FDG (P = 0.037) and (68)Ga-DOTATATE (P = 0.047).

59 (68)Ga-DOTATOC and (68)Ga-DOTATATE are radiolabeled somatostatin analogs used f

60 .92 (slope, 0.74) for (68)Ga-DOTATOC and (68)Ga-DOTATATE, respectively.

61 re scanned with both (64)Cu-DOTATATE and (68)Ga-DOTATOC PET/CT and compared on a head-to-head basis.

62 tly detected on both (64)Cu-DOTATATE and (68)Ga-DOTATOC PET/CT scans, whereas an additional 68 lesion

63 tive values for (68)Ga-OPS202 PET/CT and (68)Ga-DOTATOC PET/CT were similar ( approximately 98%).

64 ulder prostheses, or pedicle screws) and (68)Ga-labeled prostate-specific membrane antigen ((68)Ga-PS

65 F-FDG uptake, (68)Ga-DOTATOC uptake, and (68)Ga-PSMA uptake, respectively, and might therefore serve

66 ositive with both (18)F-fluciclovine and (68)Ga-PSMA-11 PET/CT, but (68)Ga-PSMA-11 PET/CT showed addi

67 egative with both (18)F-fluciclovine and (68)Ga-PSMA-11 PET/CT.

68 ion protocols, used for (18)F-DCFPyL and (68)Ga-PSMA-HBED-CC in this study, stipulate different activ

69 identified with (68)Ga-HBED-PSMA-11 and (68)Ga-THP-PSMA.

70 as (68)Ga-DOTATOC, (68)Ga-DOTATATE, and [(68)Ga-DOTA,1-Nal(3)]octreotide ((68)Ga-DOTANOC), plays an i

71 to evaluate the sst receptor antagonist (68)Ga-OPS202 ((68)Ga-NODAGA-JR11; NODAGA = 1,4,7-triazacycl

72 asing peptide receptor (GRPR) antagonist (68)Ga-SB3 ((68)Ga-DOTA-p-aminomethylaniline-diglycolic acid

73 8)Ga-prostate-specific membrane antigen ((68)Ga-PSMA) PET/CT on the management of prostate cancer in

74 eled prostate-specific membrane antigen ((68)Ga-PSMA) PET/CT scans of 7 patients with hip prostheses

75 New radiotracers, such as (68)Ga-DOTA-E-[c(RGDfK)](2), that target alphavbeta3 integri

76 th (68)Ga-labeled sstr agonists, such as (68)Ga-DOTATOC, (68)Ga-DOTATATE, and [(68)Ga-DOTA,1-Nal(3)]o

77 ion during the interval between baseline (68)Ga-DOTATATE PET/CT scan and follow-up imaging (14.0 +/-

78 is was a head-to-head comparison between (68)Ga-labeled prostate-specific membrane antigen (PSMA)-11

79 gged tilmanocept, radiolabeled with both (68)Ga and (99m)Tc.

80 For PET imaging, both (68)Ga- and (18)F-labeled agents have been successfully tran

81 compared with whole-body images for both (68)Ga-DOTATOC and (68)Ga DOTATATE.

82 ood visualization of the tumor with both (68)Ga-NeoBOMB1 and (177)Lu-NeoBOMB1.

83 ciclovine and (68)Ga-PSMA-11 PET/CT, but (68)Ga-PSMA-11 PET/CT showed additional lymph nodes metastas

84 ysis revealed that the dose delivered by (68)Ga-OPS202 to organs is similar to that delivered by othe

85 tracer (68)Ga-Glu-urea-Lys(Ahx)-HBED-CC ((68)Ga-PSMA-11) to allow accurate intraoperative detection o

86 The 2 most common (68)Ga-PSMA-11-positive lesion locations outside the consens

87 anning results and underwent comparative (68)Ga-THP-PSMA scanning.

88 grafts of the same cell lines, comparing (68)Ga-THP-PSMA with (68)Ga-HBED-CC-PSMA.

89 2, compared with the reference compound, (68)Ga-DOTATOC (an sst receptor agonist), in PET imaging.

90 Conclusion:(68)Ga-DOTATATE PET/CT enables improved detection of the tra

91 Conclusion:(68)Ga-DOTATOC PET/CT is an effective modality in the locali

92 Conclusion:(68)Ga-OPS202 showed favorable biodistribution and imaging p

93 Conclusion:(68)Ga-pentixafor PET/CT is suitable for noninvasive, highly

94 Conclusion:(68)Ga-PSMA ligand PET/CT demonstrates high detection rates

95 Conclusion:(68)Ga-PSMA PET is a promising modality in biochemical recur

96 Conclusion:(68)Ga-PSMA PET/CT altered management in 39% of patients wit

97 Conclusion:(68)Ga-PSMA-11 PET resulted in a major change in management

98 Conclusion:(68)Ga-PSMA-11 PET/CT at 3 h after injection showed most les

99 Conclusion:(68)Ga-RM2 PET can be used for assessment of GRPr expression

100 We confirmed (68)Ga-DOTATATE binding in macrophages and excised carotid p

101 y Oncology Group (RTOG) guidelines cover (68)Ga-PSMA-11 PET/CT-defined disease, and assess the potent

102 efficacy of gallium-68-labeled DOTATATE ((68)Ga-DOTATATE), a somatostatin receptor subtype-2 (SST2)-b

103 d sstr agonists, such as (68)Ga-DOTATOC, (68)Ga-DOTATATE, and [(68)Ga-DOTA,1-Nal(3)]octreotide ((68)G

104 abeling and high nuclide purity of final (68)Ga-PSMA(HBED), making subsequent purification steps unne

105 ons and lesion-to-background ratios; for (68)Ga-DOTANOC (B)-SUVs as well as VOIs defined by a 50% thr

106 For (68)Ga-DOTATATE, SUVmax was higher for G1 tumors and lower f

107 nd P values of 0.004 and 0.008) than for (68)Ga-DOTATOC (1.9, with an interquartile range of 1.4-2.9)

108 (slope, 0.71) and 0.92 (slope, 0.74) for (68)Ga-DOTATOC and (68)Ga-DOTATATE, respectively.

109 ; P = 0.15), despite a higher SUVmax for (68)Ga-HBED-PSMA than for (68)Ga-THP-PSMA (30.3 and 10.7, re

110 cytotoxicity and radiation dosimetry for (68)Ga-NOTA-UBI and a first-in-human evaluation to diagnose

111 Positive predictive values for (68)Ga-OPS202 PET/CT and (68)Ga-DOTATOC PET/CT were similar

112 most appropriate imaging time point for (68)Ga-OPS202 were assessed.

113 VOL and BPISUV as imaging biomarkers for (68)Ga-PSMA PET/CT in a prospective study exploring their po

114 For (68)Ga-PSMA-11 tracers, late imaging at 180 min after inject

115 17) for (18)F-DCFPyL and 66% (23/35) for (68)Ga-PSMA-HBED-CC.

116 her SUVmax for (68)Ga-HBED-PSMA than for (68)Ga-THP-PSMA (30.3 and 10.7, respectively; P < 0.01).

117 imaging agent when labeled with (68)Ga ((68)Ga-NODAGA-JR11 or (68)Ga-OPS202) and as a therapeutic ag

118 th NOTA to allow complexation to (68)Ga ((68)Ga-NOTA-UBI).

119 sicians, we investigated whether and how (68)Ga-labeled prostate-specific membrane antigen 11 ((68)Ga

120 r this purpose are (123)I/(124)I/(131)I, (68)Ga/(177)Lu, and (111)In/(86)Y/(90)Y.

121 Currently, chelating agents used in (68)Ga radiopharmaceuticals do not meet this ideal.

122 y test showed significant differences in (68)Ga-DOTATATE SUVmax between tumors with a Ki-67 of less t

123 dings indicative for tumor recurrence in (68)Ga-PSMA ligand PET/CT.

124 ction) and late (at 3 h after injection) (68)Ga-PSMA-11 PET/CT scans were retrospectively evaluated.

125 At 1 h after injection, (68)Ga-NOTA-HACA-PD1 and (68)Ga-DOTA-HACA-PD1 exhibited prom

126 aluate the association of intraprostatic (68)Ga-PSMA PET/CT findings and PSMA expression in immunohis

127 fied in previous (68)Ga-HBED-CC-Ahx-KuE ((68)Ga-HBED-CC-PSMA) PET/CT, allowing for their successful i

128 Fluorescent-labeled (68)Ga-tilmanocept allows for PET imaging and real-time intr

129 e the clinical impact of additional late (68)Ga-PSMA-11 PET/CT.

130 as to determine whether the CXCR4 ligand (68)Ga-pentixafor is suitable for imaging chronic infection

131 t both PET with a specific CXCR4 ligand, (68)Ga-pentixafor, and diffusion-weighted MRI.

132 and the first-in-human results will make (68)Ga-NOTA-UBI PET/CT an encouraging future diagnostic tech

133 Phe-Gln-Trp-Ala-Val-Gly-His-Sta-Leu-NH2 ((68)Ga-RM2) is a synthetic bombesin receptor antagonist that

134 The observed (68)Ga-RM2 PET detection rate was 71.8%.

135 E, and [(68)Ga-DOTA,1-Nal(3)]octreotide ((68)Ga-DOTANOC), plays an important role in staging and rest

136 icient cation-exchange postprocessing of (68)Ga as well as the development of a thin-layer chromatogr

137 rature syringe-and-vial radiolabeling of (68)Ga radiopharmaceuticals.

138 we anticipate clinical applicability of (68)Ga-avebehexin for imaging of alphavbeta6 tumors and fibr

139 e analyzed the diagnostic performance of (68)Ga-DOTATATE PET/CT and contrast-enhanced MRI (CE-MRI) fo

140 to the performance and interpretation of (68)Ga-DOTATATE PET/CT and describes its role in the diagnos

141 The interpretation of (68)Ga-DOTATATE PET/CT images for NET staging is consistent

142 stigated the definite clinical impact of (68)Ga-DOTATATE PET/CT on managing patients with neuroendocr

143 study confirmed a significant impact of (68)Ga-DOTATATE PET/CT on the intended management of patient

144 a direct impact on the interpretation of (68)Ga-DOTATATE PET/CT scans.

145 investigated the prognostic accuracy of (68)Ga-DOTATATE PET/CT-based analysis of tumor volume in pat

146 inverse correlation between quartiles of (68)Ga-DOTATATE TV and PFS (P = .001) and disease-specific s

147 single 150-MBq intravenous injection of (68)Ga-DOTATOC (15 mug of peptide) and 2 single 150-MBq intr

148 202, respectively, and 59% for 15 mug of (68)Ga-DOTATOC (P < 0.001).

149 metaanalysis summarizes the efficacy of (68)Ga-DOTATOC for several distinct indications and is inten

150 The tumor uptake of (68)Ga-HZ220 was blocked significantly with an excessive amo

151 tive study was to estimate the effect of (68)Ga-labeled prostate-specific membrane antigen (PSMA)-11

152 on by determining the biodistribution of (68)Ga-NeoBOMB1 and (177)Lu-NeoBOMB1.

153 C) received a single intravenous dose of (68)Ga-NOTA-AE105 (154 +/- 59 MBq; range, 48-208 MBq).

154 s the safe use and clinical potential of (68)Ga-NOTA-AE105 as a new radioligand for uPAR PET imaging

155 up of patients, the in vivo stability of (68)Ga-NOTA-AE105 was determined in collected blood and urin

156 single 150-MBq intravenous injections of (68)Ga-OPS202 (15 mug of peptide at visit 1 and 50 mug at vi

157 ignificantly higher for 15 and 50 mug of (68)Ga-OPS202 (5.3 and 4.3, with interquartile ranges of 2.9

158 single 150-MBq intravenous injections of (68)Ga-OPS202 3-4 wk apart (15 mug of peptide at visit 1 and

159 The higher tumor-to-background ratio of (68)Ga-OPS202 resulted not only in a higher detection rate o

160 study that evaluated the sensitivity of (68)Ga-OPS202, compared with the reference compound, (68)Ga-

161 OTATOC: 94% and 88% for 50 and 15 mug of (68)Ga-OPS202, respectively, and 59% for 15 mug of (68)Ga-DO

162 ed on a PET/MR system after injection of (68)Ga-pentixafor (15 MBq/kg).

163 and the signal intensity (P = 0.009) of (68)Ga-pentixafor uptake increased as the number of risk fac

164 One hour after injection of (68)Ga-pentixafor, strong signals were detected in vivo with

165 f this study was to assess the impact of (68)Ga-prostate-specific membrane antigen ((68)Ga-PSMA) PET/

166 /- 10 min after intravenous injection of (68)Ga-PSMA (mean dose, 176 MBq).

167 the SUVmax Nodes demonstrating uptake of (68)Ga-PSMA with an SUVmax of 2.0 or more were considered PS

168 of this work was to optimize labeling of (68)Ga-PSMA(HBED) using the efficient cation-exchange postpr

169 retrospectively evaluated the utility of (68)Ga-PSMA-11 PET for planning (223)RaCl2 therapy of patien

170 Post hoc analysis of (68)Ga-PSMA-11 PET/CT implied a major impact on SRT planning

171 ease, and assess the potential impact of (68)Ga-PSMA-11 PET/CT on SRT.

172 2-151.7 MBq (mean, 140.6 +/- 7.4 MBq) of (68)Ga-RM2 using a time-of-flight-enabled simultaneous PET/M

173 rwent PET/CT after the administration of (68)Ga-THP-PSMA.

174 -DOTATATE showed 42 lesions not found on (68)Ga-DOTATOC, of which 33 were found to be true-positive o

175 7 of 12 patients had disease detected on (68)Ga-PSMA-11 PET, 5 of whom had a major change in manageme

176 patients (82%) with disease detected on (68)Ga-PSMA-11 PET.

177 al and extrapelvic metastatic disease on (68)Ga-PSMA-11 PET/CT (PSMA T0N1M0 and PSMA T0N1M1 patterns)

178 (68)Ga-OPS202 ((68)Ga-NODAGA-JR11; NODAGA = 1,4,7-triazacyclononane,1-gluta

179 e sst receptor antagonist (68)Ga-OPS202 ((68)Ga-NODAGA-JR11; NODAGA = 1,4,7-triazacyclononane,1-gluta

180 beled with (68)Ga ((68)Ga-NODAGA-JR11 or (68)Ga-OPS202) and as a therapeutic agent when labeled with

181 PET scan at 120 min after injection) or (68)Ga-PSMA-HBED-CC (n = 129, 158.9 MBq, 60 min after inject

182 ns is similar to that delivered by other (68)Ga-labeled sst analogs.

183 Overall, (68)Ga-PSMA imaging led to a reclassification of stage in 90

184 Overall, (68)Ga-PSMA PET/CT scanning led to a change in planned manag

185 e prospectively evaluated carotid plaque (68)Ga-DOTATATE uptake in patients with recent carotid event

186 ith either approximately 13 MBq/250 pmol (68)Ga-NeoBOMB1 or a low ( approximately 1 MBq/200 pmol) ver

187 B comprised 6 patients who had positive (68)Ga-HBED-PSMA-11 PET/CT scanning results and underwent co

188 radical radiotherapy treatment, positive (68)Ga-PSMA scan results, and higher PSA levels.

189 eventy-six of these (75%) had a positive (68)Ga-PSMA-11 PET/CT result.

190 two of 270 patients (49%) had a positive (68)Ga-PSMA-11 PET/CT result.

191 l suspect lesions identified in previous (68)Ga-HBED-CC-Ahx-KuE ((68)Ga-HBED-CC-PSMA) PET/CT, allowin

192 pophilic balance cartridge purification, (68)Ga-HZ220 was obtained with a radiochemical yield of 56%

193 -DCFPyL and the (68)Ga-labeled reference (68)Ga-PSMA-HBED-CC.

194 Results:(68)Ga-pentixafor PET/CT was positive in 9 of 14 patients.

195 e receptor (GRPR) antagonist (68)Ga-SB3 ((68)Ga-DOTA-p-aminomethylaniline-diglycolic acid-DPhe-Gln-Tr

196 Sandostatin LAR injection and the second (68)Ga-DOTATATE study was 25.1 +/- 14.8 d.

197 Synchronous (68)Ga-labeled prostate-specific membrane antigen-avid malig

198 clerotic inflammation and confirmed that (68)Ga-DOTATATE offers superior coronary imaging, excellent

199 atible with cancer lesions suggests that (68)Ga-RM2 is a promising PET radiopharmaceutical for locali

200 The (68)Ga-DOTATATE and (18)F-FDG PET/CT findings were discordan

201 The (68)Ga-DOTATOC PET/CT was considered true-positive if the po

202 for the (68)Ga-OPS202 scans than for the (68)Ga-DOTATOC scan: the median of the mean tumor-to-backgro

203 labeled PSMA tracer (18)F-DCFPyL and the (68)Ga-labeled reference (68)Ga-PSMA-HBED-CC.

204 lesions was significantly higher for the (68)Ga-OPS202 scans than for the (68)Ga-DOTATOC scan: the me

205 lized with NOTA to allow complexation to (68)Ga ((68)Ga-NOTA-UBI).

206 he most common treatment decision due to (68)Ga-DOTATATE was initiation of peptide receptor radionucl

207 gest that (18)F-DCFPyL is noninferior to (68)Ga-PSMA-HBED-CC, while offering the advantages of (18)F

208 diacetic acid (HBED-CC)-based PET tracer (68)Ga-Glu-urea-Lys(Ahx)-HBED-CC ((68)Ga-PSMA-11) to allow a

209 mary malignancies in patients undergoing (68)Ga-labeled prostate-specific membrane antigen PET/CT for

210 c NET and unknown primary site underwent (68)Ga-DOTATOC PET/CT in a single-site prospective study.

211 ients with suspected infection underwent (68)Ga-NOTA-UBI PET/CT imaging.

212 infection of the skeleton who underwent (68)Ga-pentixafor PET/CT between April 2015 and February 201

213 The data for 51 patients who underwent (68)Ga-pentixafor PET/CT for noncardiovascular indications w

214 One hundred one patients who underwent (68)Ga-PSMA I&T PET/CT because of increasing prostate-specif

215 population of 270 patients who underwent (68)Ga-PSMA-11 PET/CT at 4 institutions for BCR after prosta

216 and PCA correlated with(18)F-FDG uptake, (68)Ga-DOTATOC uptake, and (68)Ga-PSMA uptake, respectively,

217 PET-based tracers using (68)Ga as the radioisotope have in most centers replaced SPE

218 cancer lesion visualization in men using (68)Ga-NeoBOMB1 and PET/CT is also presented.

219 of prostate cancer lesions in men using (68)Ga-NeoBOMB1 and PET/CT.

220 brane antigen (PSMA) uptake imaged using (68)Ga-PSMA-11 PET in a mouse xenograft model and in a patie

221 We validated (68)Ga-DOTATATE PET as a novel marker of atherosclerotic inf

222 Arterial wall (68)Ga-pentixafor uptake is significantly associated with su

223 alian multicenter study assessed whether (68)Ga-PSMA PET/CT imaging affects management intent in pati

224 as a PET imaging agent when labeled with (68)Ga ((68)Ga-NODAGA-JR11 or (68)Ga-OPS202) and as a therap

225 or was synthesized and radiolabeled with (68)Ga by adding generator eluate directly to a vial contain

226 aseline lung tumor volume addressed with (68)Ga-DOTA-E-[c(RGDfK)](2) PET/CT correlated with serum vas

227 All patients underwent PET/CT with (68)Ga-DOTA-E-[c(RGDfK)](2) radiotracer and blood-sample tes

228 (>/=500 scans or >/=5 y experience with (68)Ga-DOTATATE PET/CT; n = 3).

229 ence (<500 scans or <5 y experience with (68)Ga-DOTATATE PET/CT; n = 4) or a high level of experience

230 ficant clinical role in combination with (68)Ga-DOTATATE.

231 partment, the NET patients injected with (68)Ga-DOTATOC or (123)I MIBG emitted an average EDR-1m roug

232 ensitivity with the antagonist than with (68)Ga-DOTATOC: 94% and 88% for 50 and 15 mug of (68)Ga-OPS2

233 ll lines, comparing (68)Ga-THP-PSMA with (68)Ga-HBED-CC-PSMA.

234 (68)Ga-THP-PSMA was similar to that with (68)Ga-HBED-PSMA (4.7 and 5.4, respectively; P = 0.15), desp

235 the number of metastases identified with (68)Ga-HBED-PSMA-11 and (68)Ga-THP-PSMA.

236 PET/CT with (68)Ga-labeled sstr agonists, such as (68)Ga-DOTATOC, (68)Ga

237 PET/CT images with (68)Ga-NeoBOMB1 were acquired in prostate cancer patients.

238 Imaging with (68)Ga-PSMA PET/CT revealed unsuspected disease in the prost

239 Although PET/CT with (68)Ga-PSMA-11 in the diagnosis of prostate cancer (PCa) is

240 e (BCR) after radical prostatectomy with (68)Ga-PSMA-11 PET/CT in patients with serum PSA levels of l

241 PSMA-avid foci were also visualized with (68)Ga-THP-PSMA PET.

242 esions, the tumor-to-liver contrast with (68)Ga-THP-PSMA was similar to that with (68)Ga-HBED-PSMA (4

243 n to indicate the treatment plan without (68)Ga-PSMA-11 PET/CT information (Q1; n = 101), one immedia

244 Larmor precession of the three isotopes (69)Ga, (71)Ga and (75)As.

245 precession of the three isotopes (69)Ga, (71)Ga and (75)As.

246 specific microfossil populations of the 1.88 Ga Gunflint Iron Formation contain Fe-silicate and Fe-ca

247 associated with Rodinian assembly ( 1.3-0.9 Ga) are significantly different from those of other supe

248 Great Oxidation Event 2.4 billion years ago (Ga) and the last Palaeoproterozoic iron formations, depo

249 estrial habitats from c. 3.0 billion yr ago (Ga) onwards, creating localized 'oxygen oases' under a r

250 s, M[N((o-C6H4)NCH2P(i)Pr2)3], where M = Al, Ga, and In.

251 type M[(mu-OH)2 Co(NH3 )4 ]3 (NO3 )6 (M=Al, Ga) can be synthesized using Werner's century-old cluste

252 sts the trapping abilities of iBu2 AlTMP and Ga(CH2 SiMe3 )3 , structurally mapping their TMT reactio

253 Eutectic Ga-In (EGaIn) and Ga-In-Sn (Galinstan) alloys are typically used due to th

254 a mixture of two local structures, Ga I and Ga II, based on fitting experimental PDF to known crysta

255 e and the subsequent out-diffusion of In and Ga atoms toward the high-k film became more significant

256 Fluctuating Cu, In and Ga concentrations result in a wide distribution of poten

257 eneration of free carriers, both Fe-rich and Ga-rich GFO NCs exhibit a localized surface plasmon reso

258 The granules are Ga(OH)3 precipitation, which indicates immobilization or

259 Samples of nanostructured beta-Ga wires were synthesized by a novel method of metallic-

260 f Ga phases, including small spheres of beta-Ga with diameters near 15 mum.

261 doping), while the replacement of Fe(2+) by Ga(3+) cations, taking place in Ga-rich samples, produce

262 The distinctive Ga granules were deposited within the intercellular spac

263 ing exogenous citrate significantly enhanced Ga tolerance.

264 Eutectic Ga-In (EGaIn) and Ga-In-Sn (Galinstan) alloys are typica

265 ne elements (Ag, As, Ce, Co, Cs, Cu, Eu, Fe, Ga, Gd, La, Lu, Mn, Mo, Nb, Nd, Ni, Pr, Rb, Sm, Te, Ti,

266 A melting mechanism is proposed for Ga, in which the atomic structure of phase Iota breaks u

267 well-known solid-solid phase transition from Ga-I to Ga-II at low temperature.

268 as to gallium chelated NOTA-functionalities (Ga-10:1 NOTA-somatropin); (ii) native mass spectrometry

269 Although gallium (Ga) is a rare element, it is widely used in semiconducto

270 ussed beam of energetic ions, often gallium (Ga(+)), FIB can sculpt nanostructures via localised sput

271 a nickel-gallium complex featuring a Ni(0)-->Ga(III) bond that shows remarkable catalytic activity fo

272 ring a neutral (carbene-type) N-heterocyclic Ga(I) ligand.

273 l ammonium ion, x=7, 8 or 9, and M=Fe(III) , Ga(III) , Cr(III) , In(III) and Al(III) .

274 of Fe(2+) by Ga(3+) cations, taking place in Ga-rich samples, produces free electrons (n-type doping)

275 h approach along with a gradual variation in Ga-BEP for offsetting the consumption of the droplets ha

276 Copper (Cu) deficient (Cu/In + Ga = 0.76) CIGS films were designed to avoid the rather

277 is not correlated to hampering donors, (In, Ga)Cu and VSe, contrary to what has been previously repo

278 Cu(In,Ga)Se2 (CIGS) is presently the most efficient thin-film

279 InAs/(InAs,Ga)Sb type II superlattices (T2SLs) with different in-pl

280 om a eta(2)-H,H sigma-complex showing little Ga-H bond activation, through species of intermediate ge

281 eaturing stretched Ga-H and compressed M-H/M-Ga bonds, to a fully activated metal dihydride featuring

282 Roots were the main Ga accumulating sites.

283 NeoBOMB1 and (nat)Ga-, (nat)In-, and (nat)Lu-NeoBOMB1 bound to GRPR with h

284 The respective metalated species (nat)Ga-, (nat)In-, and (nat)Lu-NeoBOMB1 were also synthesize

285 alidated by reconstructing two stacked Co-Ni-Ga single crystals, and by comparison with a grain map o

286 , the physiological and molecular impacts of Ga in the model plant Arabidopsis thaliana were investig

287 perconductivity observed for the majority of Ga phases, including small spheres of beta-Ga with diame

288 rently with temperature, forming mixtures of Ga-substituted In2O3 and In-substituted beta-Ga2O3 with

289 calculations as follows: the substitution of Ga(3+) by Fe(2+) ions, occurring in Fe-rich conditions,

290 The primary symptom of Ga toxicity is inhibition of root growth.

291 s immobilization or limited translocation of Ga in A. thaliana.

292 d distribution of beta-phase precipitates on Ga-embrittled intergranular fracture surfaces of AA5083.

293 ic GFO NCs, produced under either Fe-rich or Ga-rich conditions, behave as degenerately doped semicon

294 acts from quince, quercetin-3-galactoside (Q-Ga), quercetin-3-rutinoside (Q-Ru), quercetin-3-glucosid

295 of intermediate geometry featuring stretched Ga-H and compressed M-H/M-Ga bonds, to a fully activated

296 suggested a mixture of two local structures, Ga I and Ga II, based on fitting experimental PDF to kno

297 exactly touching their neighbors inside the Ga nanowires.

298 wn solid-solid phase transition from Ga-I to Ga-II at low temperature.

299 secretion, respectively, were elevated under Ga stress, so the secretion may play a role in the resis

300 17 other elements (Na, K, V, Ni, Co, Cu, Zn, Ga, As, Se, Mo, Cd, Sn, Sb, Ba, W, and Pb), including ai